echemi logo
  • Product
  • Supplier
  • Inquiry
    Active Ingredient News
    Yingli Pharmaceutical's linperlisib Phase 2 results are gratifying, and many domestic pharmaceutical companies deploy PI3K inhibitors

    (abbreviated as Yingli Pharmaceutical) announced its self-developed new drug Linperlisib (YY-20394) for the treatment of relapsed/refractory follicular lymphoma (r/r) FL) Phase 2 registration clinical trials are initially completed .

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.